Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?

ISRN Cardiol · 2014 · PMC3933036 · PMID 24653841

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.2400

boldest claim

The sentences

showed a trendP = 0.08so close (0.05 < p ≤ 0.1)

In this trial, losartan 50 mg once daily did not prove superior efficacy as compared to captopril 50 mg three times daily and showed a trend towards higher incidence of sudden death or resuscitated cardiac arrest (HR: 1.25; 95% CI: 0.98–1.60; P = 0.08) [ 14 ].

also in 53,322 other papers

a nonsignificant trendP = 0.24not close (p > 0.1)

After a median follow-up of 4.7 years, losartan 150 mg/day significantly reduced hospital admissions for HF (HR 0.87; 95% CI: 0.76–0.98; P = 0.025) and showed a nonsignificant trend towards reduction in mortality (HR 0.94; 95% CI: 0.84–1.04; P = 0.24) as compared with losartan 50 mg/day.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.